Shanghai's Ark Biosciences Closes A+ Funding For Anti-Virals

Ark Biosciences of Shanghai raised an undisclosed amount of capital in an A+ round, led by Bioventure Investment Management. Ark is developing anti-viral candidates that target respiratory viruses, influenza and Hepatitis B. The latest round included Qiming Venture Partners, Morningside (both investors in the 2015 Series A) and Oriza Capital. Located in Zhangjiang Hi-Tech Park, Ark started a global Phase II trial of its treatment for respiratory syncytial virus (RSV) in August 2016.